Artwork

Peter Attia, MD, Peter Attia, and MD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Peter Attia, MD, Peter Attia, and MD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

#229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB

1:18:54
 
공유
 

Manage episode 345720655 series 2352826
Peter Attia, MD, Peter Attia, and MD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Peter Attia, MD, Peter Attia, and MD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

In this special episode of The Drive, we have pulled together a variety of clips from previous podcasts about cardiovascular disease to help listeners understand this topic more deeply, as well as to identify previous episodes which may be of interest. In this episode, Peter highlights the importance of understanding cardiovascular disease and why early intervention is critical. He also provides a primer on lipoproteins and explains the fallacy of the terms “good cholesterol” and “bad cholesterol.” Allan Sniderman discusses the metrics measured in routine blood work – along with the limitations of those standard panels – before explaining why apoB is a superior metric for determining risk. Additionally, Tom Dayspring explains the causal role of apoB in atherosclerotic cardiovascular disease (ASCVD) and the therapeutic goals for apoB concentration, and Peter explains how early and aggressive lowering of apoB could change the landscape of cardiovascular disease prevention.

We discuss:

  • The importance of understanding atherosclerosis early in life [2:25]
  • Defining ASCVD, its causes, and the role of cholesterol [8:00];
  • Why early prevention of atherosclerosis is critical [13:45];
  • Preventing atherosclerosis—two fatal flaws with the “10-Year Risk” approach [16:00];
  • Intro to lipids and lipoproteins: why there is no “bad” or “good” cholesterol [23:00];
  • Limitations of standard blood panels [35:45];
  • How Mendelian randomization is bolstering the case for apoB as the superior metric for risk prediction [39:30];
  • Therapeutic goals for apoB concentration [58:15];
  • How early and aggressive lowering of apoB could change the course of ASCVD [1:10:45]; and
  • More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

  continue reading

360 에피소드

Artwork
icon공유
 
Manage episode 345720655 series 2352826
Peter Attia, MD, Peter Attia, and MD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Peter Attia, MD, Peter Attia, and MD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

In this special episode of The Drive, we have pulled together a variety of clips from previous podcasts about cardiovascular disease to help listeners understand this topic more deeply, as well as to identify previous episodes which may be of interest. In this episode, Peter highlights the importance of understanding cardiovascular disease and why early intervention is critical. He also provides a primer on lipoproteins and explains the fallacy of the terms “good cholesterol” and “bad cholesterol.” Allan Sniderman discusses the metrics measured in routine blood work – along with the limitations of those standard panels – before explaining why apoB is a superior metric for determining risk. Additionally, Tom Dayspring explains the causal role of apoB in atherosclerotic cardiovascular disease (ASCVD) and the therapeutic goals for apoB concentration, and Peter explains how early and aggressive lowering of apoB could change the landscape of cardiovascular disease prevention.

We discuss:

  • The importance of understanding atherosclerosis early in life [2:25]
  • Defining ASCVD, its causes, and the role of cholesterol [8:00];
  • Why early prevention of atherosclerosis is critical [13:45];
  • Preventing atherosclerosis—two fatal flaws with the “10-Year Risk” approach [16:00];
  • Intro to lipids and lipoproteins: why there is no “bad” or “good” cholesterol [23:00];
  • Limitations of standard blood panels [35:45];
  • How Mendelian randomization is bolstering the case for apoB as the superior metric for risk prediction [39:30];
  • Therapeutic goals for apoB concentration [58:15];
  • How early and aggressive lowering of apoB could change the course of ASCVD [1:10:45]; and
  • More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

  continue reading

360 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드